Ind-Swift Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Ind-Swift Laboratories Ltd reported a 3.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 20.5%.
• Its expenses for the quarter were down by 0.8% QoQ and up 20.9% YoY.
• The net profit increased 58.4% QoQ and decreased 93.2% YoY.
• The earnings per share (EPS) of Ind-Swift Laboratories Ltd stood at 1.76 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ind-Swift Laboratories Ltd is a prominent player in the pharmaceutical industry. The company primarily focuses on the manufacturing and sale of active pharmaceutical ingredients (APIs) and intermediates. These products are crucial components for the production of pharmaceutical drugs, used widely across various therapeutic categories. Ind-Swift Laboratories operates globally, catering to both domestic and international markets. As of the latest updates available until October 2023, there are no specific recent major developments in the company's operations or strategic direction mentioned within the provided data. However, the company continues to leverage its expertise in pharmaceutical manufacturing to maintain its position in the market.

Revenue

For the quarter ending Q4FY26, Ind-Swift Laboratories Ltd reported a total income of ₹172.01 crores, which reflects a decrease of 3.6% compared to the previous quarter (Q3FY26) where the total income was ₹178.43 crores. However, on a year-over-year basis, there was a significant increase of 20.5% when compared to Q4FY25's total income of ₹142.70 crores. This substantial annual growth suggests a positive upward trend in revenue generation over the year despite the slight quarterly decline.

Profitability

The company's profitability metrics for Q4FY26 demonstrate varied performance when compared to previous periods. The profit before tax for Q4FY26 was ₹11.96 crores, experiencing a decline of 27.0% from Q3FY26, which recorded a profit before tax of ₹16.39 crores. In comparison to Q4FY25, the profit before tax decreased significantly by 94.8% from ₹230.46 crores. Despite this decline, the profit after tax for Q4FY26 stood at ₹15.11 crores, which marks a 58.4% increase from Q3FY26's ₹9.54 crores. However, this is a stark contrast to Q4FY25, which reported a profit after tax of ₹222.27 crores, representing a 93.2% YoY decrease. Earnings per share (EPS) for Q4FY26 was ₹1.76, showing a 55.8% increase QoQ but a 94.1% decline YoY from Q4FY25's EPS of ₹30.08.

Operating Metrics

Total expenses for Ind-Swift Laboratories Ltd in Q4FY26 were ₹154.91 crores, showing a slight decrease of 0.8% from the previous quarter's expenses of ₹156.19 crores. On a year-over-year basis, total expenses increased by 20.9% from ₹128.11 crores in Q4FY25. The tax component for Q4FY26 was noted as a negative ₹3.15 crores, which contrasts with Q3FY26 where the tax was ₹6.87 crores, marking a significant QoQ change of -145.9%. Comparing to Q4FY25, which had a tax amount of ₹8.19 crores, the YoY change is -138.5%. The financial data points to notable fluctuations in tax expenses, reflecting potentially impactful financial transactions or adjustments in this quarter.